Monday, 3 February 2020

Regenerative Medicine Market size and Key Trends in terms of volume and value 2019

Market Synopsis:
According to Market Research Future (MRFR)’s analysis, the global regenerative medicine market is prognosticated to mark an exponential CAGR of 25.4% during the forecast period 2016 to 2022. The popularity of regenerative medicine is growing owing to the large-scale prevalence of chronic diseases such as cancer, cirrhosis, etc. Other factors projected to catalyze the growth of the market include developments in nanotechnology, increasing incidence of degenerative diseases, etc. This has led to a drastic increase in the research and development initiatives undertaken globally for the development of effective drugs.
Investments are likely to flow towards the regenerative medicine market over the next couple of years. In addition, the support extended by the government for drug development is poised to revolutionize the future trajectory of the global market. It is also likely to benefit from technological advancements in the market.
Stem cell technology is gaining traction in the healthcare sector. Its accelerated adoption in the field of medical science is also anticipated to have a favorable impact on the expansion of the global regenerative medicine market. The players of the market are forecasted to capitalize on the gap prevailing between the demand and supply for organs. However, factors such as stringent regulations, and the high cost of the treatment are expected to check the proliferation of the regenerative medicine market through the projection period.
Market Segmentation:
on the basis of material, the regenerative medicine market has been segmented into synthetic materials, genetically engineered materials, pharmaceuticals, biologically derived materials, and others.
On the basis of therapy, the global regenerative medicine market has been segmented into stem cell biology, cellular therapy, tissue engineering, and others.
On the basis of application, the regenerative medicine market has been segmented into cord blood, oncology, urology, orthopedics, neurology, dermatology, cardiovascular, orthopedic and others.
Regional Analysis:
The global regenerative medicine market, by region, has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is currently holding the largest share of the market, accounting for 44% share. It is expected to grow significantly at a CAGR of 22.3% during the forecast period. The factors such as developments in healthcare technology, presence of advanced healthcare infrastructure, increasing burden of chronic diseases, etc.
Europe has gained control over the second-largest share of the market. It is expected to strike a high CAGR of 22.5% over the assessment period. The availability of funds coupled with the government’s support is likely to accelerate research & development activities. This, in turn, is prognosticated to boost the growth trajectory of the regional regenerative medicine market in the upcoming years.
Asia Pacific is a highly lucrative market and is expected to remain so across the review period. The rapid developments in the healthcare sector and growing patient pool are anticipated to drive the expansion of the regenerative medicine market in the region. It is estimated to mark a relatively higher CAGR and emerge as the fastest growing regional market in the foreseeable future.
Competitive Dashboard:
Some of the key players profiled in the report are Cook Biotech, Organogenesis, Stryker and RTI surgical, Baxter International, Inc., Osiris Therapeutics, CryoLife, Sanofi, LifeSciences, Advanced Cell Technology, BioMimetic Therapeutics, LifeCell Kinetic Concepts, StemCellsInc, and Medtronic.
Industry News:
In November 2018, 3D.FAB, a French additive manufacturing platform, has announced that it is working on the development of a “living bandage” using direct additive manufacturing and 3D bioprinting for treating damaged tissues.
In December 2018, Food and Drug Administration has sent Genetech, a CA-based biotechnology subsidiary of Roche, and other firms and providers offering stem cell treatments warning letters to notify about agency's regenerative medicine policy framework.

Posted by at No comments:
Labels:

Thursday, 30 January 2020

Lactose Intolerance Treatment Market 2019 Business Trends, Regional Study, Size, Share, Industry Profit Growth and Global Segments by Forecast to 2025

The Global Lactose Intolerance Treatment Market is expected to register a CAGR of 7.10% and reach USD 41,054.4 Million by 2025. Lactose Intolerance treatment is a digestive problem with an impaired ability to digest lactose. Factors such as rising cases of gastrointestinal disorders, increasing awareness about Lactose Intolerance treatment and related complications, and increased prevalence of Lactose Intolerance treatment are the driving forces for the market. However, side-effects associated with supplements is projected to restraint the market during the forecast period (2019-2025).
Market Dynamics
Lactose Intolerance treatment is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, abdominal pains, and others. There are four types of lactose intolerance, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study suggested by the Journal of Health, Population, and Nutrition in 2017, the prevalence of Lactose Intolerance treatment was significantly higher in IBS-D patients than in healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
Segmentation
The global Lactose Intolerance treatment market has been segmented by type of lactose intolerance, treatment, form, and end user. The market, based on type, has been bifurcated into primary lactose intolerance, secondary lactose intolerance, and congenital/developmental lactose intolerance. Based on form, the Lactose Intolerance treatment market has been segregated into food supplements, enzyme lactase supplements, probiotics, and others (combination products and prebiotics). By form, the global Lactose Intolerance treatment market has been segmented into tablets/capsule, powder, and liquid. On the basis of end-user, the market has been divided into home care and hospitals & clinics. 
The food supplements segment, by treatment is estimated to hold a share of 70.4% in the market.
Regional Analysis
The global Lactose Intolerance treatment market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Europe held the major market share of 42.0% in 2018. The dairy consumption in Western Europe is good in comparison to other regions of Europe and has a high per-capita consumption rate throughout the region. The Americas held the second largest market share of 28% in 2018. It is further segmented into North and Latin America. The consumption of dairy products is also distinct and variable in the Americas. Latin America, for example, is one of the fastest-growing dairy markets in the world. Consumers in this region are looking for more convenient ways to shop. They seek to purchase products from a single location or store, and it is one of the main drivers of hypermarkets and supermarkets in Latin America. Asia-Pacific is the third-largest region and held the market share of 20.0% in 2018. In terms of value, it has the largest dairy consumption, but it has the lowest per capita income spent on dairy products as it is still developing better infrastructure for the distribution of chilled dairy products. The Middle East and Africa is highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world.
Key Players
The prominent players in the global are Abbott Laboratories, Inc. (US), Nestle (Switzerland), Cargill, Incorporated (US), Dean Foods (US), Johnson & Johnson, Inc. (US), and Novozyme, (Denmark) are some of the major players in the market.
Some of the key strategies followed by players operating in the global Lactose Intolerance treatmentmarket were innovation, product development, and acquisition & mergers.
  • In March-2018, Nestlé completed its acquisition of Atrium Innovations Inc., a global leader in nutritional health products. This acquisition supports Nestlé’s pursuit of growth opportunities in consumer healthcare to complement the company’s focus on its high-growth food and beverage categories
  • In April-2017, Abbott introduced science-based nutrition drinks to help patients have a better recovery from surgery. New Ensure Surgery Immunonutrition Shake and Ensure Pre-Surgery Clear Nutrition Drink is designed for hospitals implementing surgical guidelines for enhancing patient recovery. These drinks are also lactose-free.
  • In May,2016- Dean Foods launched a new DairyPure brand, lactose free milk to its line of dairy products. DairyPure lactose-free milk delivers real dairy nutrition and delicious taste. Also, it is 100% lactose-free, making it easy to digest for those with lactose sensitivities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Medical Smart Textile Evaluated for a Healthy Growth by 2023; MRFR Releases the Insights for 2017-2027

Global Medical Smart Textile Market: Information by Technology (Wearable Technology, Textile Sensors and others), by Application (Bio-Monitoring, Surgery, Therapy and Wellness and others), by End User (Hospitals and Clinics and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027
Market Insights:
The Global Medical Smart Textile Market is expected to register a CAGR of 7.51% to reach 2,105.32 Million by 2027. Medical smart textile is a new field of research and is most widely used in the healthcare sector. Sensors are integrated into the textiles, in continuous contact with the human body, and could capture physiological changes occurring within the body. The demand for medical smart textiles is increasing due to the rising burden of diseases, evolving methods of diagnosis, and extensive use of wearable medical devices. These factors are expected to fuel the growth of the global medical smart textile market. However, the high cost of smart textiles is anticipated to hamper the market growth.
Key Players
The global medical smart textile market overview by Market research Future contains The top prominent players like Schoeller Switzerland, Vista Medical Ltd, Sensoria Inc., Gentherm, Siren, Pireta, AiQ Smart Clothing, Camira Fabrics, Carre Technologies Inc, and 3teks.
Some of the key strategies followed by players operating in the global medical smart textile market were innovation, product development, and acquisition & mergers.
  • In February 2019, Gentherm signed a partnership agreement with ThermoAnalytics, Inc., a leading thermal modeling software development firm for the advancement of human thermal comfort predictions.
  • In June 2019, Pireta developed a unique process that adds conductive metallic pattern directly into textile clothing without changing the fabric feel. These wearable smart garments and e-textile enabled physicians to diagnose diseases in their early stages and provide better treatment options. The launch of this device would help the company to increase its revenue in the future.
  • In July 2019, Camira Fabric acquired Luna Textiles, a US-based company that manufactures fabric for healthcare, hospitality, and other lounge seating purposes. This acquisition helped Camira Fabric to increase its revenue.
Market Dynamics
The rising burden of diseases is expected to fuel the growth of the global medical smart textile market during the forecast period. According to the Global Burden of Disease Study in 2017, from 1990 to 2017, the leading causes of premature deaths were neonatal disorders, ischemic heart disease, lower respiratory infections, diarrhea, chronic obstructive pulmonary disease (COPD), and strokes. These diseases accounted for more than 1 million deaths worldwide in 2017. Additionally, the Global Burden of Disease Study in 2017, stated that there was a change in the mortality rate due to excess drug-resistant tuberculosis from 2007 to 2017.
Segmentation
The global medical smart textile market has been segmented by technology, application, and end user. The market, based on technology, has been divided into wearable technology, textile sensors, and others. Based on application, the medical smart textile market has been segregated into bio-monitoring, surgery, therapy, and wellness and others. The global medical smart textile market, based on end user, has been bifurcated into hospitals and clinics and others. The hospitals and clinics held a share of 67.3% in 2018.
Regional Market Summary
The global medical smart textile market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global medical smart textile market. The growth in this region can be attributed to the extensive use of medical devices. Moreover, applications in medical engineering for monitoring vital health indicators help in maximizing the growth of the market in this region. Europe held a substantial share in the global medical smart textile market. This can be attributed to the rising government expenditure to promote the healthcare sector in the region. For instance, according to Eurostat, in 2016, healthcare expenditure per person was EUR 5,000 or higher in three EU member states that are Luxembourg (EUR 5,600), Sweden (EUR 5,100) and Denmark (EUR 5,000), as the per-person healthcare expenditure is very high in Europe and is continuously growing. Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the extensive demand for advanced medical devices and increasing applications of technology in the early diagnosis of diseases fueling the growth of the medical smart textile market in the region. The medical smart textile market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2027. The Middle East would lead the market growth in this region. Increasing awareness about medical smart textiles is expected to drive market growth during the assessment period.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Handheld Surgical Devices Market Rapidly Growing in Healthcare, Competitor Analysis, Complete Study of Current Trends and Forecast 2019-2023

Handheld Surgical Devices Market Research Report: By Application (Neurology, Orthopaedics, Cardiovascular, Urology, others), Product (Auxiliary Devices, Cutter Devices, Dilators, Forceps and Spatulas, & Others), End User – Global Forecast Till 2023
Market Scenario:
Increasing number of surgical procedures is the key factor driving the handheld surgical devices market. According to the Australian Institute of Health and Welfare, during 2015–16, there were 10.6 million hospitalisations, and 1 in 4 hospitalisations involved a surgical procedure.
The Global handheld surgical devices market is expected to grow at an approximate CAGR of 6.8% during forecast period, 2019–2023.
The handheld surgical devices are specially designed for specific surgeries. These are available in a wide variety of shapes and sizes.
Various other factors such as increasing incidence of accidents, high geriatric population, technological advancements, increasing demand for plastic & reconstructive surgery, and rising patient awareness regarding the benefits of handheld surgical devices are also expected to propel the growth of the market.
Key players
Some of the key players in the global handheld surgical devices industry are B. Braun Melsungen AG, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Pelion Surgical, Medtronic, Smith & Nephew, Johnson & Johnson, Millennium Surgical Corp, Medicon Eg, Elite Medical, Becton, Dickinson and Company (BD), Thompson Surgical, Stryker, Aspen Surgical, KLS Martin, CooperSurgical Inc., and others.
Segmentation
The global handheld surgical devices market is segmented based on application, product, end user and region.
The global market for handheld surgical devices, by application is segmented into neurology, urology, orthopedics, gynecology, cardiovascular, wound closure, and others.
The market, by product, is segmented into forceps and spatulas, retractors, dilators, graspers, auxiliary devices, cutter devices, and others. The auxiliary devices segment is further classified as clamps, cannulas, and closure devices. The cutter devices segment is further classified as trocars, lancets, and scissor. The others segment includes punches, curettes, blunt dissectors, and snares.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centres, research and academic institutes, and others. Clinics held a lucrative market share in 2017 due to rising prevalence of chronic conditions.
Regional Analysis
The Americas dominated the global market for handheld surgical devices owing to the increasing prevalence of chronic conditions, and high geriatric population.
In 2017, it was estimated that Europe stood second in the global handheld surgical devices market. This can be attributed to the increasing cases of surgical procedures, and rising research and development investments. According to the 2016 data suggested by Eurostat, around 1040.8 cases of cataract surgery and 406.2 cases of transluminal coronary angioplasty are registered in Germany.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, increasing healthcare expenditure, a rising number of surgical procedures drive the regional markets of the Asia Pacific region. On the other hand, the Middle East and Africa held least share in the global handheld surgical devices market due to the low per capita income, especially within the African region.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Cerebrospinal Fluid Management Devices Market Rapidly Growing in Healthcare, Competitor Analysis, Complete Study of Current Trends and Forecast 2019-2023

Cerebrospinal Fluid Management (CSF) Devices Market Research Report: By Product (Shunts, Valve, External Drainage System), Age Group (Paediatric, Adult, Geriatric), End User (Hospitals, Ambulatory Settings, and others) – Global Forecast Till 2023
Market scenario
Rising cases of hydrocephalus is one of the key factors driving the cerebrospinal fluid management (CSF) devices market. According to the Brain Foundation, one in every 1,000 Australian children is born with hydrocephalus annually.
Global cerebrospinal fluid management (CSF) devices market growth is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 4.5% over the forecast period.
Various other factors such as rising research & development expenditure, geriatric population, technological advancements, growing adoption of minimally invasive procedures, and rising awareness about hydrocephalus are also expected to propel the growth of the market.
However, lack of trained professionals, side-effects associated with the treatment, and high cost of devices can hinder the market growth over the forecast period.
Key players
Medtronic plc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, DePuy Synthes, Spiegelberg GmbH & Co. KG, SOPHYSA, Natus Medical Incorporated, Dispomedica GmbH, Delta Surgical Limited, Argi Grup, Moller Medical GmbH, G. SURGIWEAR LTD., Wellong Instruments Co., Ltd., BeckerSmith Medical, Inc., and others.
Segmentation
The Global cerebrospinal fluid management (CSF) devices market is segmented based on product, age group, end user, and region.
The Global market for cerebrospinal fluid management (CSF) devices, by product is segmented into shunts, valve, and external drainage systems.
The shunts segment is further classified as ventriculoperitoneal (VP), ventriculoatrial (VA), lumboperitoneal (LP), and ventriculopleural (VPL). The valve segment is further classified as fixed, and adjustable. The external drainage systems segment is further classified as external ventricular drainage (EVD) systems, and lumbar drainage (LD) systems.
Based on age group, the market is segmented into paediatric, adult, and geriatric.
Based on end user, the market is segmented into hospitals, ambulatory settings, clinics, research and academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The cerebrospinal fluid management (CSF) devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebrospinal fluid management (CSF) devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cerebrospinal fluid management (CSF) devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebrospinal fluid management (CSF) devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for cerebrospinal fluid management (CSF) devices owing to the rising geriatric population and presence of major market players. As per the 2018 statistics suggested by the U.S. Census Bureau, by 2035, there will be 78 million people 65 years and older compared to 76 million under the age of 18.
In 2017, it was estimated that Europe stood second in the global cerebrospinal fluid management (CSF) devices market. This can be attributed to the rising research and development investments and increasing technological advancements.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and rising cases of hydrocephalus drives the regional markets of the Asia Pacific region. According to the Hydrocephalus association, approximately 200,000 cases of congenital hydrocephalus in infants are registered around the world. However, in India, nearly 12,000 cases of congenital hydrocephalus are registered each year.
On the other hand, the Middle East and Africa held least share in the global cerebrospinal fluid management (CSF) devices market due to the low per capita income and stringent government policies, especially within the African region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Amyotrophic Lateral Sclerosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 – 2023

ALS or Amyotrophic Lateral Sclerosis is a neurological ailment which affects the nerve cells in the spinal cord and the brain that controls the voluntary muscles’ activities. Some of the common symptoms of ALS include cramps, muscle weakness, respiratory problems, and fasciculation. This is a progressive neurological disease where gradually patients become dependent on physicians and caregivers increasingly. Often ALS results in respiratory failure as the patient loses the ability of controlling the muscles both in the diaphragm and the chest. Ultimately, it turns fatal.
Additional factors such as the inclination towards the sedentary lifestyle are driving the market growth and increasing the risk of developing ALS. Besides, the increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options.
The Global Amyotrophic Lateral Sclerosis Market size by valuation is expected to surpass USD 841.6 million by 2023, growing at approximately 7.89 % CAGR over the forecast period (2019-2023). In 2017, the market had a valuation of USD 526 million.
But the high cost of the treatment of ALS may hinder the market growth over the forecast period.
Segments                                                                                                                                            
The Global amyotrophic lateral sclerosis market has been segmented on the basis of type, treatment, and end-user.
By type, the market is segmented into sporadic and familial ALS. The sporadic ALS, also abbreviated as SALS, was the largest segment in 2017 and can dominate the market over the forecast period.
By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. Out of these, medication had the largest market in 2017.
By end-user, the ALS market has been segmented into hospitals, specialty centers, research & academic institutes, and others. Among these, the subsegment Hospital accounts for the largest segment.
Regional Analysis
By Regions, the global amyotrophic lateral sclerosis market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is estimated to dominate the global ALS market owing to the increasing pool of awareness and the rising prevalence of hypertension. ALS remains a significant public health challenge in the US. Therefore, governments and private non-profit organizations are developing specific guidelines for the management and treatment of ALS. Public and private organizations are involved in strategic partnerships and collaborations in search for a better outcome in the research of amyotrophic lateral sclerosis treatment in the region.
The amyotrophic lateral sclerosis market in the European region stands at the second position in terms of the market size mainly due to the well-established healthcare sector. Several companies and research institutes are also establishing advanced facilities to research ALS.
Moreover, in recent years, there has been an increase in the adoption of sedentary lifestyles among people. Research shows that an increase in physical activities such as exercise helps in reducing the pain and thwarting some of the symptoms such as loss of motion in patients who have ALS.
Thus, the inclination towards the sedentary lifestyle increases the risk of developing ALS among the elderly population, thus creating a demand for symptomatic and targeted treatment options. The development of novel therapeutic approaches and advanced treatment options are likely to push the growth of the amyotrophic lateral sclerosis market during the forecast period.
Whereas, the ALS market in the Asia Pacific region is expected to grow rapidly due to the increasing prevalence of the disease and rapidly developing healthcare infrastructure. The increasing economy in the region is playing a vital role in the growth of the market. Furthermore, the increase in the setups of research and development centers also fuels the growth of the ALS market in the region.
Key Players                                                                                                         
  • Sun Pharmaceutical (India),
  • Mitsubishi Tanabe Pharma America (U.S.),
  • Biogen (U.S.),
  • Sanofi (France),
  • Mylan N.V. (U.S.),
  • Covis Pharma (Switzerland),
  • Ionis Pharmaceutical (U.S.),
  • ITF Pharma (U.S.),
  • Ascend Pharmaceuticals LLC (U.S.),
  • Apotex Inc. (Canada).
Feb 2019- Leading technology transfer company, BGN Technologies has lately disclosed about a new AI (artificial intelligence) platform to monitor and predict the development of neurodegenerative diseases in order to identify markers both for improved drug development and personalized patient care. This technology will focus on ALS at an initial stage and later on will be adapted to other neurodegenerative diseases namely Alzheimer’s and Parkinson’s. The latest technology will predict disease progression more accurately, a key component for clinical trials along with better identifying the interrelationships amid demographics and many other measurable factors that are identified through patient functionality and physical examinations. It will allow researchers in creating a system which insurers, HMOs, pharmaceutical companies, caregivers, physicians, and patients can use on mobile applications and desktop for monitoring and predicting ALS progression.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Rectovaginal Fistula Market 2019 Global Industry Trends, Statistics, Size, Share, Growth Factors, Emerging Technologies, Regional Analysis, Competitive Landscape Forecast to 2023

Global Rectovaginal Fistula Market Research Report: by Diagnosis (Physical Exam, Contrast Tests, Blue Dye Test, Computerized Tomography (CT) Scan) By Treatment (Medications, Surgery) By End User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2023
Market Scenario
As per the Birth Injury Guide, estimates show that between 700 and 900 women die every year due to pregnancy or childbirth-related complications in United States.
Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth. However, the high cost of surgery may restraint the market growth during the assessment period.  
Due to increasing focus on research and development in treatment of diseases, moreover increasing applications in cancer treatment are the factors responsible to boost the market growth during assessment period. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.
The Global Rectovaginal Fistula Treatment Market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. 
Key players
Some of the prominent players in the global rectovaginal fistula market are Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others
Segmentation
The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Regional Market Summary
On regional basis, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the growing R&D budgets by both government as well as commercial pharmaceutical and biotechnological companies and increasing adoption of advanced technologies in the region.  Europe is expected to hold the second largest position in the global rectovaginal fistula market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia Pacific has served an opportunity for rectovaginal fistula market in this region due to increasing demand for the better treatment and devices and increasing prevalence of disease like cancer. The Middle East & Africa has the least share of the global rectovaginal fistula market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.   
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)